China Biotech Podcast: Going Global Trends, Rare Disease Drug Development
Internationalization 'A Must' for China Biotechs
Executive Summary
Guest speaker Professor Guangzuo Luo joins Brian Yang and Dexter Yang to discuss orphan drug development and going global trends for Chinese bioventures, along with the latest business moves from Shanghai Fosun and Jiangsu Hengrui.
This time, Guangzuo Luo, founder and chief scientific officer of Nanjing-based Bioncetech, joins China-based Scrip editors Brian Yang and Dexter Yan in this Chinese-language podcast to talk about his views on the challenges and opportunities around developing orphan drugs in China.
Luo is also a professor at China Medical University and has years of experience developing gene therapies, including the first US-approved adeno-associated virus-based gene therapy, Spark Therapeutics, Inc.'s Luxturna (voretigene neparvovec) for an inherited retinal disease.
He also discusses Bioncetech's pipeline, which includes candidates for common conditions.
In the second part of the podcast, Brian talks about his coverage of recent moves by Jiangsu Hengrui Medicine Co., Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to go global.
He highlights the three main options for Chinese biotechs pursuing internationalization, other recent trends and how a full acquisition of Shanghai Henlius Biotech Co. Ltd. by Fosun might benefit the latter’s overseas expansion goals.
罗光佐教授是贝思奥生物创始人董事长，中国医科大学教授、博导，美国宾夕法尼亚大学博士后，中国科学院遗传学博士。他的丰富行业经验包括世界上第一例上市的AAV基因治疗起源地宾大（Upenn）、CHOP和基因治疗公司Spark Therapeutics 。
他从早研立项、临床等角度阐述目前中国罕见病药物出海的机会和挑战，以及，考虑到国内目前的融资环境和政策条件，为支持罕见病药物研发，企业可以采取哪些对策？最后，他介绍了除了罕见病以外，公司还研发包括针对肿瘤，神经系统和眼科疾病等常见病的候选新药。
在第二部分，我们讨论了中国药企出海目前都有三种方式，江苏恒瑞的出海最新呈现有哪些特点，以及，复星和复宏汉霖会进一步合并，在出海策略上借助复宏汉霖的生物类似药的成功可以达到哪些目的，等等。
(Also see "China Rare Disease Firms Aspire To Global Stage" - Scrip, 30 May, 2024.)
(Also see "Fosun To Fully Acquire Henlius In Go-Global Push?" - Scrip, 26 May, 2024.)